Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Samsung, Biogen Advance Biosimilars Joint Venture | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Samsung, Biogen Advance Biosimilars Joint Venture

Establish Samsung Bioepis, begin Korea R&D site

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Samsung Biologics and Biogen Idec have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars. The JV is part of the biosimilars agreement the companies announced in December.

Christopher Hansung Ko has been named the chief executive officer of Samsung Bioepis. He previously served as senior vice president of Samsung Strategic Business Development. The JV’s board of directors will consist of five directors and one auditor.

The strategic collaboration between Samsung Biologics and Biogen Idec will enable Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars. Construction of Samsung Bioepis’ R&D center, located at Samsung Biologics’ site in Song-do Incheon, Korea, has started and will be completed by the end of the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics